Numerical , albeit non-significant , improvement in acute exacerbations of COPD , SGRQ-C , CRQ-SAS , and FEV1 were greater in benralizumab-treated patients with baseline blood eosinophil concentrations of 200 cells per L or more or 300 cells per L or more .